TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7574828

Group type: EXPERIMENTAL
Intervention: Sunscreen plus UVB (SPF 29 sunscreen containing octyl methoxycinnamate, oxybenzone, and octyl salicylate) followed by three minimal erythema doses of UVB irradiation.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: UVB group (three minimal erythema doses of UVB irradiation without sunscreen).
Number of subjects: 29

Group type: COMPARATOR
Intervention: No-UVB group (control group with no prior exposure to UVB).
Number of subjects: 29
Study: 2710641

Group type: EXPERIMENTAL
Intervention: Carbamazepine divitabs (sustained-release formulation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbamazepine normal formulation (ordinary tablets)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carbamazepine divitabs
Number of subjects: 20
Study: 7015139

Group type: EXPERIMENTAL
Intervention: Tamoxifen combined with L‐phenylalanine mustard and 5‐fluorouracil
Number of subjects: 0
Study: 31522806

Group type: EXPERIMENTAL
Intervention: HIV vaccine with 85% efficacy
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: HIV vaccine with 50% efficacy
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Altruistic attitudes
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Higher educational attainment
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Vaccine-related social concerns
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Altruism
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 137
Study: 28714882

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20 drops of Vigantol oil, 1904 IU/d)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo oil (medium chain triglycerides)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 59
Study: 26822091

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Exercise recovery
Number of subjects: 27

Group type: COMPARATOR
Intervention: Insulin stimulation
Number of subjects: 27
Study: 25108506

Group type: EXPERIMENTAL
Intervention: Standard online weight loss program (n=94)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Enhanced online weight loss program with personalized feedback (n=98)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Wait-list control group (n=97)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Enhanced online program (n=98)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: ARFS and sub-scale scores (fruit, meat, wholegrain, dairy, water)
Number of subjects: 289
Study: 22858133

Group type: EXPERIMENTAL
Intervention: Pre-operative muscle activation patterns of the quadriceps and gastrocnemius muscle groups during gait
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Prolonged activation of the vastus medialis muscle and higher activation of the lateral gastrocnemius muscle during early stance
Number of subjects: 37
Study: 20352320

Group type: EXPERIMENTAL
Intervention: Microenterprise intervention (tailoring of canvas bags)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 18998062

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle punctures and aspiration of calcareous deposits
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ultrasound-guided punctures only
Number of subjects: 81
Study: 15800784

Group type: EXPERIMENTAL
Intervention: (18)F‐fluorodeoxyglucose (FDG) PET
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Voxel-based morphometry (VBM) analysis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 30
Study: 12090782

Group type: EXPERIMENTAL
Intervention: formoterol 9 microg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: formoterol 18 microg
Number of subjects: 20

Group type: COMPARATOR
Intervention: salbutamol 100 microg
Number of subjects: 20

Group type: COMPARATOR
Intervention: salbutamol 200 microg
Number of subjects: 20
Study: 10528871

Group type: EXPERIMENTAL
Intervention: 99mTc‐HMPAO uptake
Number of subjects: 25

Group type: COMPARATOR
Intervention: Neuropsychological testing
Number of subjects: 25
Study: 7653319

Group type: EXPERIMENTAL
Intervention: Behavioral marital therapy (BMT) with relapse prevention (RP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Behavioral marital therapy (BMT) without relapse prevention (RP)
Number of subjects: 74
Study: 2207995

Group type: EXPERIMENTAL
Intervention: Proglumide
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 7105797

Group type: EXPERIMENTAL
Intervention: Timolol (10 mg twice daily)
Number of subjects: 732
Study: 31852482

Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction exercise (BFRE) for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no exercise) for 12 weeks
Number of subjects: 22
Study: 27838498

Group type: EXPERIMENTAL
Intervention: Video teleconferencing (VTC)
Number of subjects: 128

Group type: COMPARATOR
Intervention: In-person (IP)
Number of subjects: 128
Study: 26563197

Group type: EXPERIMENTAL
Intervention: Hysteroscopic niche resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management (Control)
Number of subjects: 0
Study: 24941763

Group type: EXPERIMENTAL
Intervention: Low BTXA group (1 U/10(6) Cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High BTXA group (2.5 U/10(6) Cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BTXA groups (both low and high)
Number of subjects: 0
Study: 22965588

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham injection (Control)
Number of subjects: 19
Study: 19300235

Group type: EXPERIMENTAL
Intervention: 3 doses of trimethoprim‐sulfamethoxazole at urinary catheter removal
Number of subjects: 239

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 239
Study: 17179353

Group type: EXPERIMENTAL
Intervention: 140 kVp
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 120 kVp
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 100 kVp
Number of subjects: 62

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 62
Study: 15325937

Group type: EXPERIMENTAL
Intervention: Tirofiban infusion before percutaneous coronary intervention
Number of subjects: 0
Study: 11563799

Group type: EXPERIMENTAL
Intervention: Laboratory setting
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: On-campus bar setting
Number of subjects: 39
Study: 9781932

Group type: EXPERIMENTAL
Intervention: Saterinone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Number of subjects: 12
Study: 8091463

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) at 1 g per kg per day for 2 consecutive days each week for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous saline placebo administered according to the same schedule as IVIG
Number of subjects: 12
Study: 3045553

Group type: EXPERIMENTAL
Intervention: High-monounsaturated-fat diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 10
Study: 29759857

Group type: EXPERIMENTAL
Intervention: 3 doses of IV‐TXA at 3‐hour intervals (group C)
Number of subjects: 150
Study: 28916599

Group type: EXPERIMENTAL
Intervention: DA+DCB
Number of subjects: 102

Group type: COMPARATOR
Intervention: DCB
Number of subjects: 102
Study: 26253488

Group type: EXPERIMENTAL
Intervention: SEQ-IMRT
Number of subjects: 122

Group type: COMPARATOR
Intervention: SIB-IMRT
Number of subjects: 122
Study: 23158592

Group type: EXPERIMENTAL
Intervention: Half volume group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Resting volume group
Number of subjects: 80
Study: 21146270

Group type: EXPERIMENTAL
Intervention: eGFR <30 mL/min/1.73 m(2)
Number of subjects: 15336

Group type: EXPERIMENTAL
Intervention: eGFR 30-44 mL/min/1.73 m(2)
Number of subjects: 15336

Group type: EXPERIMENTAL
Intervention: eGFR 45-59 mL/min/1.73 m(2)
Number of subjects: 15336

Group type: EXPERIMENTAL
Intervention: eGFR ≥75 mL/min/1.73 m(2)
Number of subjects: 15336

Group type: EXPERIMENTAL
Intervention: Dipstick-positive proteinuria
Number of subjects: 15336

Group type: EXPERIMENTAL
Intervention: eGFR <30 mL/min/1.73 m(2) and dipstick-positive proteinuria
Number of subjects: 15336
Study: 20633367

Group type: EXPERIMENTAL
Intervention: High-frequency bilateral rTMS (20 trains of 10 Hz at 110% of the RMT, administered daily for 3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 20
Study: 16479736

Group type: EXPERIMENTAL
Intervention: Personalized asthma desensitization (previously specific immunotherapy, SIT)
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Usual medications (control group)
Number of subjects: 1182
Study: 12207596

Group type: EXPERIMENTAL
Intervention: Intermittent fluticasone propionate (FP) cream 0.05% (twice per week)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Vehicle cream/emollients
Number of subjects: 372
Study: 10477967

Group type: EXPERIMENTAL
Intervention: Home-sampling and mailing urine/vaginal flush samples to the laboratory
Number of subjects: 8909

Group type: COMPARATOR
Intervention: Examination by a physician
Number of subjects: 8909
Study: 8567611

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy adapted for sexually abused preschool children (CBT-SAP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nondirective supportive therapy (NST)
Number of subjects: 67
Study: 1858672

Group type: EXPERIMENTAL
Intervention: Bepridil (200 to 400 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Diltiazem (median 360 mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 86

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 86
Study: 6337083

Group type: EXPERIMENTAL
Intervention: Cimetidine (1.6 gm daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 30874782

Group type: COMPARATOR
Intervention: Moderate-intensity intervention (Arm 2)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: High-intensity intervention (Arm 3)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Low-intensity intervention (Arm 1)
Number of subjects: 6000
Study: 30062633

Group type: EXPERIMENTAL
Intervention: Xuebijing Injection (XBJ)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 50
Study: 27440003

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 8598
Study: 24566584

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Number of subjects: 4685

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 4685

Group type: COMPARATOR
Intervention: Patient Mailing
Number of subjects: 4685
Study: 22251061

Group type: EXPERIMENTAL
Intervention: OptiNose powder device (Opt‐Powder)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Traditional liquid spray pump (Spray)
Number of subjects: 7
Study: 19935106

Group type: EXPERIMENTAL
Intervention: Spleen artery embolization (SAE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (nonembolized patients)
Number of subjects: 16
Study: 16438474

Group type: EXPERIMENTAL
Intervention: Ropinirole (0.25-4.0 mg once daily, 1 to 3 hours before bedtime)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 12695313

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 7152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7152
Study: 11204324

Group type: EXPERIMENTAL
Intervention: Rehabilitation with impulsive magnetic field therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Rehabilitation without impulsive magnetic field therapy
Number of subjects: 54
Study: 8823858

Group type: EXPERIMENTAL
Intervention: Intranasal phenylephrine drops
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 1408294

Group type: EXPERIMENTAL
Intervention: Alfentanil by PKPCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine by PKPCA
Number of subjects: 0
Study: 2416161

Group type: EXPERIMENTAL
Intervention: PUVA treatment
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 29
Study: 30600223

Group type: EXPERIMENTAL
Intervention: Brochures
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Scripted conversation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 3‐minute video
Number of subjects: 62
Study: 29202611

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: High Aurora A expression
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Moderate Aurora A expression
Number of subjects: 1323
Study: 27611985

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) 100 units/kg, subcutaneous injection on days 1, 3, 6, 9, and 12
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO)
Number of subjects: 159
Study: 24614619

Group type: EXPERIMENTAL
Intervention: TIVA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study: 23088620

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 267
Study: 20861451

Group type: EXPERIMENTAL
Intervention: Vitamins B(12), B(6), and folic acid supplementation
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 18570009

Group type: EXPERIMENTAL
Intervention: Diet with specially processed cereals (SPC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 82
Study: 16206587

Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 147
Study: 12296922

Group type: EXPERIMENTAL
Intervention: Small SJM standard valves (19 mm or 21 mm)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Small SJM Hemodynamic Plus (HP) valves
Number of subjects: 68

Group type: COMPARATOR
Intervention: Large-size SJM standard valve (23 mm or larger)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Group 1 (small aortic annulus)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Group 2 (large aortic annulus)
Number of subjects: 68
Study: 10522284

Group type: EXPERIMENTAL
Intervention: Self-controlled use of physical assistance devices (ski poles)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Yoked group (no influence on pole/no-pole schedule)
Number of subjects: 2
Study: 8770779

Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Music tape
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ICU environmental noise tape
Number of subjects: 15
Study: 1785361

Group type: EXPERIMENTAL
Intervention: Standard treatment (low-salt diet 70 to 90 mEq of Na per day, stopping diuretics and laxatives, elastic stockings) + carbidopa/levodopa 25/100 (3 tabs/day) + captopril 6.25 mg q 8 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard treatment (low-salt diet 70 to 90 mEq of Na per day, stopping diuretics and laxatives, elastic stockings)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patients with IE
Number of subjects: 10
Study: 6783363

Group type: EXPERIMENTAL
Intervention: Noxytiolin instillation during radical radiotherapy
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (no Noxytiolin) during radical radiotherapy
Number of subjects: 242
Study: 30975143

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg, twice daily for 12 months)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control (on-demand treatment)
Number of subjects: 161
Study: 28205322

Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI 2.0 mg
Number of subjects: 365

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI
Number of subjects: 365

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 365
Study: 26297649

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 22452770

Group type: EXPERIMENTAL
Intervention: Painful heat stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpainful warm stimulation
Number of subjects: 0
Study: 21372444

Group type: COMPARATOR
Intervention: LAC (lansoprazole 30 mg + amoxicillin 750 mg + clarithromycin 200 mg bid for 1 week)
Number of subjects: 74

Group type: COMPARATOR
Intervention: LAC2E (lansoprazole 30 mg bid + amoxicillin 750 mg bid + clarithromycin 200 mg bid + ecabet sodium 2 g bid for 1 week)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: LA2E (lansoprazole 30 mg bid + amoxicillin 750 mg bid + ecabet sodium 2 g bid for 2 weeks)
Number of subjects: 74
Study: 19141090

Group type: EXPERIMENTAL
Intervention: Adjunctive devices during percutaneous coronary intervention (PCI)
Number of subjects: 5728

Group type: EXPERIMENTAL
Intervention: Thrombectomy devices
Number of subjects: 5728

Group type: COMPARATOR
Intervention: Adjunctive devices
Number of subjects: 5728
Study: 17367324

Group type: EXPERIMENTAL
Intervention: Excised lesions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Prospective follow-up at 3-month intervals for at least 1 year (mean 6.8 months)
Number of subjects: 90
Study: 14979943

Group type: EXPERIMENTAL
Intervention: One per cent silver nitrate gel
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.1 per cent silver nitrate gel
Number of subjects: 44
Study: 10929023

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after high-dose chemotherapy (BEAM regimen)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 15
Study: 9382536

Group type: EXPERIMENTAL
Intervention: Neoadjuvant intra-arterial infusion chemotherapy (Epirubicin on Days 1, 3, 5, 7 + MPA 1,200 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Adjuvant intravenous chemotherapy
Number of subjects: 21
Study: 8452102

Group type: EXPERIMENTAL
Intervention: Toremifene (20 to 200 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no antiestrogen)
Number of subjects: 0
Study: 3095698

Group type: EXPERIMENTAL
Intervention: Standard influenza vaccine (V)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg/day (Al)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg/day (A2)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo (VP)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo (AP)
Number of subjects: 333
Study: 31089818

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) combined with steroid therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Steroid therapy alone
Number of subjects: 57
Study: 29737804

Group type: EXPERIMENTAL
Intervention: Palm olein
Number of subjects: 120

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 120
Study: 26563670

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 μg
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo Respimat
Number of subjects: 464
Study: 25356053

Group type: EXPERIMENTAL
Intervention: Somatostatin for 5-7 days starting 6 hours after the operation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 120
Study: 22251332

Group type: EXPERIMENTAL
Intervention: Belbin team role groups
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-Belbin control groups
Number of subjects: 62
Study: 20236611

Group type: EXPERIMENTAL
Intervention: Soda commercials
Number of subjects: 51

Group type: COMPARATOR
Intervention: Water commercials
Number of subjects: 51
Study: 18616856

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy (PHT)
Number of subjects: 0
Study: 15966959

Group type: EXPERIMENTAL
Intervention: ACT-ID
Number of subjects: 0

Group type: COMPARATOR
Intervention: SCT-ID
Number of subjects: 0
Study: 11835911

Group type: EXPERIMENTAL
Intervention: L-arginine (600 mg/6 ml)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (6 ml)
Number of subjects: 50
Study: 12063159

Group type: EXPERIMENTAL
Intervention: Sertraline alone (50-200 mg)
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) alone (10 sessions)
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Sertraline plus IPT
Number of subjects: 707

Group type: COMPARATOR
Intervention: Sertraline alone
Number of subjects: 707

Group type: COMPARATOR
Intervention: IPT alone
Number of subjects: 707
Study: 9701539

Group type: EXPERIMENTAL
Intervention: High formalization
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low formalization
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 72
Study: 8602903

Group type: EXPERIMENTAL
Intervention: Colgate Total toothbrush
Number of subjects: 193

Group type: COMPARATOR
Intervention: New Improved Crest Complete toothbrush
Number of subjects: 193

Group type: COMPARATOR
Intervention: Reach Advanced Design toothbrush
Number of subjects: 193

Group type: COMPARATOR
Intervention: Oral‐B Advantage toothbrush
Number of subjects: 193
Study: 2645243

Group type: EXPERIMENTAL
Intervention: Kitecko ultrasonic conductor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water path system (IV bag)
Number of subjects: 100
Study: 31823937

Group type: EXPERIMENTAL
Intervention: Quadpill (irbesartan 37.5 mg, amlodipine 1.25 mg, hydrochlorothiazide 6.25 mg, atenolol 12.5 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29165570

Group type: EXPERIMENTAL
Intervention: Active arm with charge display showing maximum allowable Medicare reimbursement rate for tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm without charge display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0